Literature DB >> 10613676

Successful epistaxis control in a patient with Glanzmann thrombasthenia by increased bolus injection dose of recombinant factor VIIa.

A Chuansumrit, C Sangkapreecha, P Hathirat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10613676

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  5 in total

Review 1.  Recombinant factor VIIa: a review on its clinical use.

Authors:  Massimo Franchini
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

Review 2.  The use of recombinant activated factor VII in platelet disorders: a critical review of the literature.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2009-01       Impact factor: 3.443

3.  Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII.

Authors:  Paris Margaritis; Valder R Arruda; Majed Aljamali; Rodney M Camire; Alexander Schlachterman; Katherine A High
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 4.  Recombinant activated factor VII in clinical practice: a 2014 update.

Authors:  Massimo Franchini; Silvia Crestani; Francesco Frattini; Cinzia Sissa; Carlo Bonfanti
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

Review 5.  Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.

Authors:  Man-Chiu Poon
Journal:  Vasc Health Risk Manag       Date:  2007
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.